Journal of Neuro-Oncology

, Volume 85, Issue 1, pp 65–73 | Cite as

Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China

  • Zhongqiang Lu
  • Yanyan Cao
  • Yimin Wang
  • Qingjun Zhang
  • Xianghong Zhang
  • Shuheng Wang
  • Yuehong Li
  • Huiling Xie
  • Baohua Jiao
  • Jianhui Zhang
Lab. Investigation-human/animal tissue/


The single nucleotide polymorphisms (SNPs) in the promoter region of matrix metalloproteinase (MMP) genes may influence tumor occurrence and progression via modifying mRNA transcription and protein expression. The study aims to explore the association of the SNPs in MMP-1, 3 and MMP-9 promoters with susceptibility to adult brain astrocytoma in northern China. Genotyping for the MMP-1 -1607 2G/1G, MMP-3 -1171 5A/6A, and MMP-9 -1562 C/T SNPs were performed by PCR-RFLP methods among 236 adult astrocytoma patients and 366 healthy controls. The results showed that the overall distribution of the MMP-1 allelotype and genotype among astrocytoma patients and healthy controls was significantly different (P = 0.002 and P < 0.001, respectively). Compared with the 2G/2G genotype, the 1G/1G genotype significantly decreased the risk of astrocytoma development (adjusted OR = 0.58, 95% CI = 0.42–0.79). The similar results were obtained when stratified by gender and age at tumor diagnosis (≤45 or >45 years). The association between MMP-3 -1171 5A/6A or MMP-9 -1562 C/T SNPs and susceptibility to astrocytoma was not observed in this study. However, MMP-1 1G-MMP-3 6A haplotype significantly reduced the risk of astrocytoma development when using MMP-1 2G-MMP-3 6A haplotype as a reference (OR = 0.45, 95% CI = 0.29–0.67). The present study suggested that, the MMP-1 -1607 1G/1G genotype and MMP-1 1G-MMP-3 6A haplotype may play protective role in the development of adult astrocytoma in northern Chinese, whereas the MMP-3 -1171 5A/6A and MMP-9 -1562 C/T polymorphisms may not be independent factors to influence susceptibility to adult astrocytoma in this population.


Matrix metalloproteinase Single nucleotide polymorphism Glioma astrocytoma Susceptibility 



We greatly appreciate Drs. Yu Qi and Yinan Ma in the Central Laboratory of the First Affiliated Hospital of Beijing University to provide technique support in experiment assays.


  1. 1.
    Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 15(8–9):535–541PubMedCrossRefGoogle Scholar
  2. 2.
    Johnsen M, Lund LR, Romer J, Almholt K, Dano K (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10(5):667–671PubMedCrossRefGoogle Scholar
  3. 3.
    Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189(3):300–308PubMedCrossRefGoogle Scholar
  4. 4.
    Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C (1997) Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 57(21):4882–4888PubMedGoogle Scholar
  5. 5.
    Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, Kahari VM (1999) Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 154(2):469–480PubMedGoogle Scholar
  6. 6.
    Skobe M, Fusenig NE (1998) Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 95(3):1050–1055PubMedCrossRefGoogle Scholar
  7. 7.
    Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R (2003) A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200(1):49–55PubMedCrossRefGoogle Scholar
  8. 8.
    Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y (2003)A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 106(3):372–374PubMedCrossRefGoogle Scholar
  9. 9.
    Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D (2002) Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62(22):6430–6433PubMedGoogle Scholar
  10. 10.
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R (2002) A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8(12):3820–3823PubMedGoogle Scholar
  11. 11.
    Szyllo K, Smolarz B, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A (2002) The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res 21(3):357–361PubMedGoogle Scholar
  12. 12.
    Ghilardi G, Biondi ML, Erario M, Guagnellini E, Scorza R (2003) Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms. Clin Chem 49(11):1940–1942PubMedCrossRefGoogle Scholar
  13. 13.
    Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88(3):197–204PubMedCrossRefGoogle Scholar
  14. 14.
    Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W (2005) A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131(1):19–25PubMedCrossRefGoogle Scholar
  15. 15.
    Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58(23):5321–5325PubMedGoogle Scholar
  16. 16.
    Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM (1995) Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73(3):209–215PubMedGoogle Scholar
  17. 17.
    Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM (1996) Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271(22):13055–13060PubMedCrossRefGoogle Scholar
  18. 18.
    Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J (2001) Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69(6):851–859PubMedGoogle Scholar
  19. 19.
    van Kempen LC, Coussens LM (2002) MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2(4):251–252PubMedCrossRefGoogle Scholar
  20. 20.
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S (1999) Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q 12.2–13.1. Hum Genet 105(5):418–423PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99(14):1788–1794PubMedGoogle Scholar
  23. 23.
    Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M (2002) Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 102(5):526–529PubMedCrossRefGoogle Scholar
  24. 24.
    Zhu Y, Spitz MR, Lei L, Mills GB, Wu X (2001) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61(21):7825–7829PubMedGoogle Scholar
  25. 25.
    Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF, Zhang JH (2005) No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 11(16):2385–2389PubMedGoogle Scholar
  26. 26.
    Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G, Dong Z (2004) The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25(12):2519–2524PubMedCrossRefGoogle Scholar
  27. 27.
    Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J (2005) Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 26(2):481–486PubMedCrossRefGoogle Scholar
  28. 28.
    Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J (2005) No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49(2):155–161PubMedCrossRefGoogle Scholar
  29. 29.
    Malmer B, Gronberg H, Bergenheim AT, Lenner P, Henriksson R (1999) Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study. Int J Cancer 81(3):366–370PubMedCrossRefGoogle Scholar
  30. 30.
    Ichimura K, Ohgaki H, Kleihues P, Collins VP (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70(2):137–160PubMedCrossRefGoogle Scholar
  31. 31.
    Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, Miike R, Barger G, Wrensch M (2004) Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 64(22):8468–8473PubMedCrossRefGoogle Scholar
  32. 32.
    Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M (2002) History of allergies among adults with glioma and controls. Int J Cancer 98(4):609–615PubMedCrossRefGoogle Scholar
  33. 33.
    Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M (2005) Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 65(14):6459–6465PubMedCrossRefGoogle Scholar
  34. 34.
    Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Aldape K, McMillan A, Wiencke JK (2004) Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol Biomarkers Prev 13(3):461–467PubMedGoogle Scholar
  35. 35.
    Rajaraman P, Schwartz BS, Rothman N, Yeager M, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD (2005) Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect 113(9):1209–1211PubMedCrossRefGoogle Scholar
  36. 36.
    Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW (2005) Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 137(1–2):98–103PubMedCrossRefGoogle Scholar
  37. 37.
    Lu Z, Wang Y, Zhang Q, Zhang X, Wang S, Xie H, Li Y, Jiao B, Zhang J (2006) Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res 1118(1):6–12PubMedCrossRefGoogle Scholar
  38. 38.
    McCready J, Broaddus WC, Sykes V, Fillmore HL (2005) Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer 117(5):781–785PubMedCrossRefGoogle Scholar
  39. 39.
    Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215PubMedCrossRefGoogle Scholar
  40. 40.
    Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli PL, Federici G, Cortese C (2000) Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20(6):1600–1605PubMedGoogle Scholar
  41. 41.
    Ferrand PE, Parry S, Sammel M, Macones GA, Kuivaniemi H, Romero R, Strauss JF III (2002) A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. Mol Hum Reprod 8(5):494–501PubMedCrossRefGoogle Scholar
  42. 42.
    Wang M, Wang T, Liu S, Yoshida D, Teramoto A (2003) The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20(2):65–72PubMedCrossRefGoogle Scholar
  43. 43.
    Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21(3):105–112PubMedCrossRefGoogle Scholar
  44. 44.
    Li Y, Jin X, Kang S, Wang Y, Du H, Zhang J, Guo W, Wang N, Fang S (2006) Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 101(1):92–96PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Zhongqiang Lu
    • 1
  • Yanyan Cao
    • 2
  • Yimin Wang
    • 2
  • Qingjun Zhang
    • 3
  • Xianghong Zhang
    • 4
  • Shuheng Wang
    • 4
  • Yuehong Li
    • 4
  • Huiling Xie
    • 1
  • Baohua Jiao
    • 1
  • Jianhui Zhang
    • 2
  1. 1.Department of NeurosurgeryThe Second Hospital of Hebei Medical UniversityShijiazhuangChina
  2. 2.Hebei Cancer InstituteHebei Medical UniversityShijiazhuangChina
  3. 3.Department of NeurosurgeryThe Renmin Hospital of Beijing UniversityBeijingChina
  4. 4.Department of PathologyThe Second Hospital of Hebei Medical UniversityShijiazhuangChina

Personalised recommendations